skip banner navigation
National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials Search Results
Quick Links
Dictionary

Funding Opportunities

NCI Publications

NCI Calendar

Español
NCI Highlights
Chemo Extends Life in Advanced Prostate Cancer

Temozolomide Plus Radiation Helps Brain Cancer

Confirmed: Raloxifene Drops Risk of Breast Cancer

Bortezomib Delays Progression of Multiple Myeloma

Annual Report to the Nation

Past Highlights
Need Help?
Results: 31-40 of 229   Show     results per page
 View Search Criteria | Help With Results
Sort By:    Version:    Format:   
Last Modified: 8/27/2004     First Published: 10/1/1999  

31.
Phase I/II Randomized Pilot Study of p53 Peptide Vaccine and Low-Dose Interleukin-2 in Patients With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II, Phase I
Treatment
Active
18 and over
NCI
NCI-99-C-0138
NCI-NMOB-9902, NCI-T99-0075

Last Modified: 7/2/2004     First Published: 3/1/1999  

32.
Phase I/II Study of Ras Peptide Cancer Vaccine With or Without Interleukin-2 in HLA-A2-1-Positive Patients With Locally Advanced or Metastatic Colorectal Cancer
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II, Phase I
Treatment
Active
Over 18
NCI
NCI-99-C-0023J
NCI-T98-0034

Last Modified: 6/8/2004     First Published: 8/1/1998  

33.
Phase I/II Study of Extended Field Radiotherapy With Concurrent Paclitaxel and Cisplatin Chemotherapy in Patients With Previously Untreated Carcinoma of the Cervix Metastatic to the Para-aortic Lymph Nodes
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II, Phase I
Treatment
Active
18 and over
NCI
GOG-9804

Last Modified: 6/8/2004     First Published: 8/1/1998  

34.
Phase I/II Study of Radiotherapy Combined With Paclitaxel and Cisplatin in Patients With Stage IB2, IIA, IIB, IIIB, or IVA Invasive Carcinoma of the Cervix
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II, Phase I
Treatment
Active
18 and over
NCI
GOG-9803

Last Modified: 7/1/2000     First Published: 11/26/2002  

35.
Phase I/II Study of Yttrium Y 90 Labeled Humanized Anti-Tac Monoclonal Antibody and Pentetic Acid Calcium in Patients With Tac Expressing Hematologic Malignancies Other Than Adult T-cell Leukemia
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II, Phase I
Supportive care, Treatment
Active
18 and over
NCI
NCI-97-C-0110F

Last Modified: 8/3/2004     First Published: 11/26/2002  

36.
A Pilot Study Of Paclitaxel/Cyclophosphamide and High-Dose Melphalan/Etoposide With Autologous Progenitor Cell Transplantation For the Treatment Of Inflammatory Breast Cancer
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II, Phase I
Treatment
Active
18 and over
NCI
NCI-96-C-0104
NCI-T95-0078N

Last Modified: 5/27/2003     First Published: 11/26/2002  

37.
Phase I/II Study of Immunization With Dendritic Cells Presenting Epitopes Derived from the Melanoma Associated Antigens MART-1 and gp100 With or Without Interleukin-2 in Patients With Metastatic Melanoma
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II, Phase I
Treatment
Active
18 and over
NCI
NCI-97-C-0046
NCI-97-C-0019, NCI-T96-0046N

Last Modified: 4/15/2004     First Published: 11/26/2002  

38.
EPOCH Chemotherapy Plus Rituximab For Previously Treated Patients With AIDS-Associated Lymphoma
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II
Treatment
Active
18 and over
NCI
NCI-97-C-0040G
NCI-T96-0036N

Last Modified: 2/23/2004     First Published: 11/26/2002  

39.
Phase II Study of Interferon alfa in Patients With Grade I, II, or III Lymphomatoid Granulomatosis and of Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab in Patients With Grade III Lymphomatoid Granulomatosis
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II
Treatment
Active
12 and over
NCI
NCI-94-C-0074
NCI-MB-325

Last Modified: 9/5/2003     First Published: 12/1/1997  

40.
Phase II Study of Fludarabine in Patients With Intermediate- or High-Risk Untreated B-Cell Chronic Lymphocytic Leukemia
Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase II
Treatment
Active
18 and over
NCI
NCI-97-C-0178

   Select All on One Page
Refine Search   Display for Print   New Search < Previous  1 2 3 4 5 6 7   Next >
skip footer navigation

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health FirstGov.gov